ResearcherHong Kong Baptist UniversityActive in the last 2 years
Zhu Zhang
Matched on ORCID iD 0000-0001-5009-4680; OpenAlex author ID A5100382791. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2020: 1 paper · 2021: none · 2022: 3 papers · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 5
- Isoliquiritigenin from Licorice Attenuates Metastatic Development of Pancreatic Cancer by Regulation of Selective Autophagy-Mediated Ferroptosis and the Tumor … Co-author DOI 10.1142/s0192415x26500710↗
- Isoliquiritigenin inhibits pancreatic cancer progression through blockade of p38 MAPK-regulated autophagy. Co-author DOI 10.1016/j.phymed.2022.154406↗
- The human cathelicidin peptide LL-37 inhibits pancreatic cancer growth by suppressing autophagy and reprogramming of the tumor immune microenvironment. Co-author DOI 10.3389/fphar.2022.906625↗
- MUC1 is responsible for the pro-metastatic potential of calycosin in pancreatic ductal adenocarcinoma. First author PMID 35968328↗
- The dual roles of calycosin in growth inhibition and metastatic progression during pancreatic cancer development: A "TGF-β paradox". Co-author DOI 10.1016/j.phymed.2020.153177↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Joshua Ka-Shun Ko · 5 shared papers, 2020–2026 · strength 1.01
- Paper Isoliquiritigenin from Licorice Attenuates Metastatic Development of Pancreatic Cancer by Regulation of Selective Autop… DOI 10.1142/s0192415x26500710↗
- Paper MUC1 is responsible for the pro-metastatic potential of calycosin in pancreatic ductal adenocarcinoma. PMID 35968328↗
- Paper Isoliquiritigenin inhibits pancreatic cancer progression through blockade of p38 MAPK-regulated autophagy. DOI 10.1016/j.phymed.2022.154406↗
- Aiping Lü · 1 shared paper, 2026 · strength 0.32
- Wenqing Chen · 1 shared paper, 2022 · strength 0.22
- Bin Liu · 1 shared paper, 2022 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.